Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (244)
  3. Review (13)
  4. Guidelines (10)
  5. Research Letter (9)
  6. Book Section (6)
  7. Editorial (4)
  8. Correspondence (3)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (664)
  2. Department of Medicine (664)
  3. Hematologic Malignancies, Division of (664)
  4. Lymphoma (664)
  5. Population Sciences Research Program (664)
  6. Survivorship Research (170)

More Groups

People
  1. Alison Moskowitz (231)
  2. Andrew Zelenetz (166)
  3. Paul Hamlin (137)
  4. Ariela Noy (136)
  5. David Straus (121)
  6. Maria Palomba (109)

More People

Years
  1. 2025 (12)
  2. 2024 (50)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Annals of Oncology (18)
  5. Blood Advances (18)
  6. Leukemia and Lymphoma (18)

More Publications

Publishers
  1. American Society of Hematology (276)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (33)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (22)

More Publishers

Results (664)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab versus investigator's choice in the treatment of patients with relapsed/refractory adult T-cell leukemia-lymphoma: Overall response rate, progression-free survival, and overall survival
    Meeting Abstract

    Phillips, A.; Fields, P.; Hermine, O.; Ramos, J. C.; Beltran, B. E.; Pereira, J.; Brites, C.; Wandroo, F. A.; Lill, M.; Feldman, T. A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult T-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga)
    Meeting Abstract

    Phillips, A. A.; Horwitz, S. M.; Taylor, G. P.; Humphrey, J. S.; Tobinai, K.; Ishida, T.; Ueda, R.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: Clinical efficacy in a CITN multicenter phase 2 study
    Meeting Abstract

    Khodadoust, M.; Rook, A. H.; Porcu, P.; Foss, F. M.; Moskowitz, A. J.; Shustov, A. R.; Shanbhag, S.; Sokol, L.; Shine, R.; Fling, S. P.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 alcanza study
    Meeting Abstract

    Kim, Y. H.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Dummer, R.; Scarisbrick, J. J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Wang, Y.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • The outcome of patients with primary refractory or relapsed peripheral T-cell lymphoma: Analysis of 1020 cases registered in the prospective T-cell project
    Meeting Abstract

    Bellei, M.; Foss, F. M.; Horwitz, S. M.; Marcheselli, L.; Kim, W. S.; Cabrera, M. E.; Dlouhy, I.; Nagler, A.; Advani, R. H.; Pesce, E.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Differential outcome of patients with primary refractory vs. relapsed peripheral T-cell lymphoma: Analysis from a prospective multicenter US cohort study
    Meeting Abstract

    Lansigan, F.; Horwitz, S. M.; Pinter-Brown, L. C.; Carson, K. R.; Shustov, A. R.; Rosen, S. T.; Pro, B.; Hsi, E. D.; Federico, M.; Gisselbrecht, C.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save